Bioqual(OTC) BIOQ

Bioqual, Inc. is a leading provider of preclinical research solutions, specializing in both in-vivo and in-vitro methodologies. The company serves a diverse clientele, including commercial enterprises and government agencies, focusing on critical health domains such as COVID-19, AIDS, and oncology.

Products and Services

• Preclinical research solutions for various health domains
• Advanced laboratory capabilities for biological sample processing
• Support for studies utilizing animal research models

Growth Outlook

• Revenue of $9.84 million in the latest quarter, showing resilience
• Strong cash position with $11.26 million in cash and equivalents
• Current ratio of 4.01 indicates robust liquidity

Financial Highlights

• Trailing twelve months (TTM) revenue of $39.5 million
• Net income margin of -0.03, reflecting ongoing investment in growth
• Operating cash flow of $1.2 million in the latest quarter

Bioqual, Inc. has established itself as a key player in the medical diagnostics and research industry. The company's focus on preclinical research solutions positions it well to capitalize on the growing demand for innovative health solutions. Recent financial performance indicates a solid revenue stream, with a TTM revenue of $39.5 million, despite a net income margin of -0.03, which suggests ongoing investments in growth and development. The latest quarterly results show a revenue of $9.84 million, reflecting the company's ability to maintain a steady income stream even in challenging market conditions. The company's liquidity is strong, as evidenced by a current ratio of 4.01, indicating that it can easily cover its short-term liabilities. Additionally, Bioqual's cash position of $11.26 million provides a buffer for future investments and operational needs. Overall, Bioqual, Inc. presents a compelling opportunity for investors interested in the healthcare sector, particularly in the realm of preclinical research and diagnostics.